Celecoxib added to risperidone for schizophrenia
About this title
Read the official source — NCT00639483This study evaluated the effectiveness of Celecoxib for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Celecoxib for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- La Plata and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 270
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Argentina, Brazil, Germany, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT00639483
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
La Plata, Argentina · Lanus, Argentina · PR, Brazil
12 more locations
- Salvador, Brazil
- Aparecida de Goiânia, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Bonn, Germany
- München, Germany
- Münster, Germany
- Mexico City, Mexico
- Mandaluyong, Philippines
- Pasig, Philippines
- Niao-Sung Hsiang, Taiwan
- Taipei, Taiwan
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Celecoxib for people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including Celecoxib and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
